Yazar "Geredeli, Çağlayan" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    Akut varis dışı üst GİS kanamalarının tedavisinde somatostatin ile famotodinin karşılaştırılması
    (Dicle Üniversitesi, Tıp Fakültesi, 1999) Geredeli, Çağlayan; Canoruç, Fikri
    Somatostatinin özofagus varis kanamaları ndaki etkinliği hakkında bir çok çalışma yapılmış ve çoğunda sonuç somatostatin lehine olmuştur. Fakat bu ilacın varis dışı üst GİS kanamaları ndaki etkinliği belirsizdir. Çünkü yapılan çalışmalar farklı sonuçlar vermiştir. Bu nedenle somatostatinin varis dışı üst GİS kanamaları ndaki etkinliğini bir H2 reseptör blokeri olan famotidin ile karşılaştırmak amacıyla 42 hasta üzerinde denedik. Hastalardan 21 'ine somatostatin, 250 meg puşe ve daha sonra 250 meg/saat infüzyon, diğer 21 hastaya ise famotidin 20 mg IV bolus günde 2 defa uygulandı. Hastalar 120 saat boyunca yoğun bakımda takip edildi. Her iki ilacında kanmayı durdurmasına, kanamayı durdurma zamanına, 120 saat boyunca gerekli olan kan transfüzyonu ihtiyacına, hastalarda tedavi esnasında ilk 120 saat içinde gelişen rekürren kanama oranlarına ve cerrahi gerekliliklerine bakıldı. Somatostatin hastaların %95.2'inde kanamayı durdururken, famotidin hastaların %90.4'ünde kanamayı durdurdu. Her iki ilaçta kanamayı anlamlı olarak durdurdu. Aralarında kanamayı durdurma açısından istatistiksel fark bulunamadı (p>0.05). Somatostatin kanamayı H2 reseptör blokeri olan famotidine göre anlamlı derecede kısa sürede durdururken, kan transfüzyonu ihtiyacını, rekürren kanama oranları ve cerrahi gereklilik açısından famotidin ile aralarında anlamlı fark saptanmadı. Ancak kan transfüzyonu ihtiyacı ve cerrahi gereklilik açısından trend somatostatin lehine idi. Sonuç olarak, somatostatinin pahalı olması ve kullanımının daha zor olması dikkate alındığında, famotidin kullanımının somatostatin kullanımına göre daha cost effective olduğu kanaatine varılmıştır.
  • [ X ]
    Öğe
    Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer
    (BMJ Publishing Group, 2022) İlhan, Yusuf; Tatlı, Ali Murat; Teker, Fatih; Önder, Arif Hakan; Köse, Fatih; Geredeli, Çağlayan; Kaplan, Muhammet Ali; Oruç, Zeynep
    Objective Cisplatin-paclitaxel and bevacizumab is a frequently used treatment regimen for metastatic or recurrent cervical cancer, and carboplatin-paclitaxel and bevacizumab are also among the recommended regimens. In this study we aimed to evaluate the efficacy of these two regimens for the treatment of metastatic or recurrent cervical cancer. Methods Patients with metastatic or recurrent cervical cancer treated with cisplatin-paclitaxel and bevacizumab or carboplatin-paclitaxel and bevacizumab were retrospectively evaluated in this study. The clinical and demographic characteristics of patients in each group were evaluated. Median overall survival, progression-free survival, and response rates between the two groups were compared. Results A total of 250 patients were included. Overall, the numbers of patients with recurrent disease and metastatic disease were 159 and 91, respectively. The most common histologic subtype was squamous cell carcinoma (83.2%). The median duration of follow-up was 13.6 (range 0.5-86) months. The median progression-free survival was 10.5 (95% CI 9.0 to 11.8) months in the cisplatin-paclitaxel and bevacizumab group (group 1), and 10.8 (95% CI 8.6 to 13.0) months in the carboplatin-paclitaxel and bevacizumab group (group 2) (HR 1.20; 95% CI 0.88 to 1.63; p=0.25). The median overall survival was 19.1 (95% CI 13.0 to 25.1) months in group 1 and 18.3 (95% CI 15.3 to 21.3) months in group 2 (HR 1.28; 95% CI 0.91 to 1.80; p=0.15). Conclusions There is no survival difference between cisplatin or carboplatin combined with paclitaxel and bevacizumab in metastatic or recurrent cervical cancer
  • Küçük Resim
    Öğe
    Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study
    (Future Medicine LTD., 2022) Yasin, Ayşe İrem; Aydın, Sabin Göktaş; Sümbül, Bilge; Koral, Lokman; Şimşek, Melih; Geredeli, Çağlayan; Kalkan, Ziya
    Aim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 non-cancer volunteers. An IgG level >= 50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: ClinicalTrials.gov) Plain language summary Cancer patients are at high risk for infection with SARS-CoV-2 and of developing the associated disease, COVID-19, which therefore puts them in the priority group for vaccination. This study evaluated the efficacy and safety of CoronaVac, an inactivated virus vaccine, in cancer patients. The immune response rate, defined as seropositivity, was 85.2% in the cancer patient group and 97.5% in the control group. The levels of antibodies, which are blood markers of immune response to the vaccine, were also significantly lower in the patient group, especially in those older than 60 years and receiving chemotherapy. These results highlight the importance of determining the effective vaccine type and dose in cancer patients to protect them from COVID-19 without disrupting their cancer treatment.